Compare PPG Industries, Inc. (PPG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs TG Therapeutics Inc — how do they compare? PPG Industries, Inc. trades at $103.96 (market cap $23.44B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: PPG Industries, Inc. is far larger — about 2.9× TG Therapeutics Inc's market cap, and PPG Industries, Inc. pays a 2.81% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and TG Therapeutics Inc for 16 Days on average.
| PPG | TGTX | |
|---|---|---|
Market Cap | $23.44B | $8.16B |
Volume | 2,064,777 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $59.06 |
52-Week Low | $94.34 | $26.94 |
Typical Hold Time | 68 Days | 16 Days |
Enterprise Value | $29.31B | $8.37B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG trades at $105.45, up 0.35% today, with a bearish technical signal and mixed earnings history including a Q2 2026 miss. The company maintains solid profitability with a 9.57% net margin and 19.63% ROE, supported by $1.94B operating cash flow in 2025. Recent news highlights margin pressures in automotive refinish but also innovation initiatives and leadership appointments.
Outlook is cautiously optimistic given the 55% analyst buy rating and $130 consensus price target, implying 23% upside. Risks include segment-specific weakness and macroeconomic sensitivity, but strong cash generation and dividend payments provide stability. The stock offers value at a P/E of 15.13, though near-term performance hinges on Q3 2026 results due Oct 27.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
